/ Active, not recruitingPhase 2 A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)
This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma
100 Clinical Results associated with Cothera Bioscience, Inc.
0 Patents (Medical) associated with Cothera Bioscience, Inc.
100 Deals associated with Cothera Bioscience, Inc.
100 Translational Medicine associated with Cothera Bioscience, Inc.